Question · asked by 0 reviews
Summary of findings ‐ Niprisan® vs placebo: Frequency of severe complications of SCD
- Population
- people with sickle cell disease
- Intervention
- Summary of findings ‐ Niprisan®
- Comparison
- placebo
- Outcome
- Frequency of severe complications of SCD
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings ‐ Niprisan® vs placebo Frequency of severe complications of SCD · adults and children with sickle cell disease Phytomedicines (medicines derived from plants) for sickle cell disease (2018) · Cochrane Headline outcomes onlyearlier version CD004448.PUB6, superseded | no estimate extracted | 70 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Summary of findings ‐ Niprisan® vs placebo · people with SCD · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.